This report is not a personal recommendation and does not take into account your personal circumstances or appetite for risk.
The below stocks have been identified as having potential to register bigger than normal share price moves (up or down) today based on the news cited
Shire to be replaced by generic drugmaker Hikma Pharma from 24 Dec, ahead of Shire’s $60bn takeover by Takeda in early January.
AstraZeneca (& Merck) get’s US approval for Lynparza for advanced ovarian cancer; cut progression/death by 70% vs placebo, after platinum chemotherapy; Results from another PIII trial expected H2 2019. PIII trials for Roxadustat (kidney disease patients with Anemia) also positive.
Kier Group raises net £250m from 33-for-50 rights issue at 409p per new share (6% premium to yesterday’s close). However, it only received 37.66% acceptance for the fully underwritten rights issue.
Greencore to return £509m to shareholders via tender offer at 195p/share (17.5% prem to yesterday’s close); to run until 29 Jan, with any unrealised funds to be returned via special dividend.
Stagecoach to sell North American unit to private equity firm Variant for $271.4m ($207m cash, $64.4m net debt transfer); proceeds to pay down debt.
(Sources: Company newswires, Bloomberg, CNBC, FT, Reuters, Wall Street Journal)
For more information on any of these individual news items, call into the trading floor
| Stock | Code | Close | High | Low |
| GLAXOSMITHKLINE | GSK | 2.4% | 6.8% | 2.4% |
| GLENCORE | GLEN | 0.5% | 1.1% | -4.1% |
| BARCLAYS | BARC | -0.9% | 0.4% | -1.2% |
| SHIRE | SHP | -2.2% | -1.3% | -2.8% |
| GVC | GVC | 0.6% | 6.4% | -0.4% |
| FLYBE | FLYB | 4.7% | 20.9% | -0.3% |
This research is produced by Accendo Markets Limited. Research produced and disseminated by Accendo Markets is classified as non-independent research, and is therefore a marketing communication. This investment research has not been prepared in accordance with legal requirements designed to promote its independence and it is not subject to the prohibition on dealing ahead of the dissemination of investment research. This research does not constitute a personal recommendation or offer to enter into a transaction or an investment, and is produced and distributed for information purposes only.
Accendo Markets considers opinions and information contained within the research to be valid when published, and gives no warranty as to the investments referred to in this material. The income from the investments referred to may go down as well as up, and investors may realise losses on investments. The past performance of a particular investment is not necessarily a guide to its future performance.
Prepared by Michael van Dulken, Head of Research